A Phase 3 interventional study of ForeCYTE Breast Aspirator in Breast Cancer, Preneoplastic Conditions, BRCA, sponsored by Atossa Therapeutics, Inc.. Withdrawn at 2 sites in Israel. Open to female participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-25.
Sponsored by Atossa Therapeutics, Inc. · Phase 3, Interventional, and Screening
The purpose of this study is to measure the performance of the ForeCYTE Breast Aspirator for the collection and processing of Nipple Aspirate Fluid (NAF) specimens for cytology. Including collecting, processing and shipping samples, training staff, processing samples, sample interpretation and accurate and timely reporting in a manner resembling routine clinical use. The study will include a subset of patients who are known carriers of a BRCA germline mutation. NAF from this subset will be submitted for molecular testing in addition to cytology.
12,815 studies on the registry are indexed under Breast Neoplasms; 2,920 are open to participants now.
Browse Breast Neoplasms studies →Atossa Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy, female, age 30-55 years, from whom bi-lateral specimens can be obtained.
The following additional considerations apply:
Women with prior mastectomy/lumpectomy may be considered for NAF-collection in the contralateral (non-operated) breast only if they were:
Exclusion Criteria
Nipple Aspirate is collected using the ForeCYTE Breast Aspirator
Device: ForeCYTE Breast Aspirator
NAF cytological classification(s), according to the modified King Classification.
Time frame: 1 day (single time point)
The IBIS (Tyrer-Cuzick) risk score (10-year and lifetime breast cancer risk estimate.
Time frame: 1 day (single time point)
Safety, as reported by adverse events experienced after NAF collection with ForeCYTE Breast Aspirator
Time frame: 1 day (single time point)
micro-RNA (subgroup analysis of BRCA mutation carriers only)
development of micro-RNA panel that signals the transition to breast cancer
Time frame: 1 day (single time point)
This study is withdrawn, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atossa Therapeutics, Inc.